临床药物基因组学实施联盟（CPIC）华法林给药的药物基因组学指导原则：2017年更新版
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
作者信息
Johnson J A, Caudle K E, Gong L, Whirl-Carrillo M, Stein C M, Scott S A, Lee M T, Gage B F, Kimmel S E, Perera M A, Anderson J L, Pirmohamed M, Klein T E, Limdi N A, Cavallari L H, Wadelius M
机构信息
Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.
Abstract
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
摘要
本文档是2011年临床药物基因组学实施联盟（CPIC）关于CYP2C9和VKORC1基因分型与华法林剂量指南的更新版。当有临床基因检测结果时，本文呈现了来自已发表文献的证据，用于基于CYP2C9、VKORC1、CYP4F2和rs12777823基因分型指导华法林剂量调整，以达到国际标准化比值2-3的目标。此外，这份更新后的指南纳入了针对不同大陆血统的成人和儿童患者的建议。
相似文献
1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.
2
A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
J Clin Pharm Ther. 2021 Jun;46(3):640-648. doi: 10.1111/jcpt.13334. Epub 2020 Dec 21.
3
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Syst Rev. 2016 Jun 23;5(1):105. doi: 10.1186/s13643-016-0280-y.
4
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7.
5
Warfarin pharmacogenetics.
Trends Cardiovasc Med. 2015 Jan;25(1):33-41. doi: 10.1016/j.tcm.2014.09.001. Epub 2014 Sep 6.
6
Pharmacogenetics of Warfarin in a Diverse Patient Population.
J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):521-533. doi: 10.1177/1074248419843530. Epub 2019 May 7.
7
Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
Eur J Clin Pharmacol. 2019 Jul;75(7):901-911. doi: 10.1007/s00228-019-02656-7. Epub 2019 Mar 9.
8
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.
9
Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Pharmacol Rep. 2021 Oct;73(5):1405-1417. doi: 10.1007/s43440-021-00256-w. Epub 2021 Apr 3.
10
Race influences warfarin dose changes associated with genetic factors.
Blood. 2015 Jul 23;126(4):539-45. doi: 10.1182/blood-2015-02-627042. Epub 2015 May 29.
引用本文的文献
1
Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study.
BMJ Open. 2025 Aug 27;15(8):e091562. doi: 10.1136/bmjopen-2024-091562.
2
The history and future of pharmacogenetics in Aotearoa/New Zealand.
J R Soc N Z. 2024 Oct 6;55(6):2422-2439. doi: 10.1080/03036758.2024.2406824. eCollection 2025.
3
Implementation of genetic testing for heritable cardiac conditions: A scoping review.
Genet Med Open. 2025 Jun 30;3:103441. doi: 10.1016/j.gimo.2025.103441. eCollection 2025.
4
Major Allele Frequencies in and in Asian and European Populations: A Case Study to Disaggregate Data Among Large Racial Categories.
J Pers Med. 2025 Jun 27;15(7):274. doi: 10.3390/jpm15070274.
5
Assessment of Time in Therapeutic Range (TTR) in a Primary Care Warfarin Clinic.
Cureus. 2025 Jun 9;17(6):e85653. doi: 10.7759/cureus.85653. eCollection 2025 Jun.
6
A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.
NPJ Genom Med. 2025 Jul 10;10(1):54. doi: 10.1038/s41525-025-00511-6.
7
A Prediction Model of Stable Warfarin Doses in Patients After Mechanical Heart Valve Replacement Based on a Machine Learning Algorithm.
Rev Cardiovasc Med. 2025 Jun 26;26(6):33425. doi: 10.31083/RCM33425. eCollection 2025 Jun.
8
Polygenic and pharmacogenomic contributions to medication dosing: a real-world longitudinal biobank study.
J Transl Med. 2025 Jul 2;23(1):727. doi: 10.1186/s12967-025-06782-y.
9
Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system.
NPJ Genom Med. 2025 Jul 1;10(1):50. doi: 10.1038/s41525-025-00508-1.
10
Anticoagulation Failure in Stroke: Causes, Risk Factors, and Treatment.
J Stroke. 2025 May;27(2):195-206. doi: 10.5853/jos.2025.00206. Epub 2025 May 31.
本文引用的文献
1
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Clin Pharmacol Ther. 2017 May;101(5):675-683. doi: 10.1002/cpt.558. Epub 2016 Dec 29.
2
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
3
Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans.
J Cardiovasc Pharmacol. 2016 Jan;67(1):86-92. doi: 10.1097/FJC.0000000000000317.
4
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2. Epub 2015 Mar 11.
5
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Pharmacogenet Genomics. 2015 Feb;25(2):73-81. doi: 10.1097/FPC.0000000000000108.
6
Characterizing variability in warfarin dose requirements in children using modelling and simulation.
Br J Clin Pharmacol. 2014 Jul;78(1):158-69. doi: 10.1111/bcp.12308.
7
A randomized trial of genotype-guided dosing of warfarin.
N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.
8
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19.
9
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.
10
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
Eur J Clin Pharmacol. 2013 Jun;69(6):1275-83. doi: 10.1007/s00228-012-1466-4. Epub 2013 Jan 11.
Zotero 插件